Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026
Company Medical Device

Lifetech’s IBS Angel Stent System Gains EU CE MDR Certification

Fineline Cube Mar 10, 2023

China-based Lifetech Scientific Corporation (HKG: 1302) has announced that it has received CE MDR certification...

Company Deals

Olipharma Secures Funding for Manufacturing Expansion in Pre-Series A+ Round

Fineline Cube Mar 10, 2023

Olipharma, a Contract Development and Manufacturing Organization (CDMO) specializing in small nucleic acid drugs and...

Company Drug

Inventiva and Chia Tai Tianqing’s Lanifibranor Advances with CDE Filing

Fineline Cube Mar 10, 2023

France-based Inventiva S.A. and China’s Chia Tai Tianqing have successfully filed a clinical trial application...

Company Drug

Simcere’s SIM0237 Begins Clinical Study for PD-L1 and IL-15 Targeting Bispecific Antibody

Fineline Cube Mar 10, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the first patient in (FPI) a clinical...

Deals Drug

AusperBio and Asymchem Form Strategic Partnership for Drug Development

Fineline Cube Mar 10, 2023

China-based firms AusperBio and Asymchem (SHE: 002821, HKG: 6821) have entered into a strategic partnership...

Policy / Regulatory

NHSA’s 2022 Healthcare Security Bulletin Reveals Break-Even Performance

Fineline Cube Mar 10, 2023

The National Healthcare Security Administration (NHSA) has released its annual “Healthcare Security Development Statistical Bulletin”...

Company Drug

Bio-Thera Solutions Initiates Phase I Study for Trop2-Targeting ADC BAT8008

Fineline Cube Mar 10, 2023

China-based Bio-Thera Solutions, Ltd (SHA: 688177) has announced the first patient dosing in a multi-center,...

Company Drug

Astellas and Seagen File for NMPA Approval of Enfortumab Vedotin for Urothelial Carcinoma

Fineline Cube Mar 10, 2023

Japan-based Astellas Pharma Inc. (TYO: 4503) and US biotech Seagen Inc. (Nasdaq: SGEN) have announced...

Company Deals

HuiLiao Biomedical Raises RMB 100 Million in Pre-Series A Round for mRNA Development

Fineline Cube Mar 10, 2023

China-based nucleic acid drug specialist Suzhou HuiLiao Biomedical Technology Co., Ltd has reportedly raised over...

Company Drug

InnoCare Pharma Initiates Clinical Study for BCL2 Inhibitor ICP-248 in China

Fineline Cube Mar 10, 2023

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced the first subject dosing in a...

Company Deals

Thederma Pharmaceuticals Raises RMB 100 Million for AhR-Targeted Therapies

Fineline Cube Mar 10, 2023

China-based Shanghai Thederma Pharmaceuticals Co., Ltd has reportedly raised RMB 100 million (USD 14.35 million)...

Company Deals

Xinrui Medtech Secures Pre-Series A Funding for Cardiovascular Device Development

Fineline Cube Mar 10, 2023

Xinrui Medtech, a cardiovascular device maker based in Suzhou, has reportedly raised “tens of millions”...

Company Medical Device

Lifetech Scientific’s IBS Angel Stent Receives CE MDR Certification in EU

Fineline Cube Mar 10, 2023

China-based Lifetech Scientific Corporation (HKG: 1302) has announced that it has received CE MDR certification...

Company Deals

Olipharma Raises Funds in Pre-Series A+ Round to Expand Manufacturing Facilities

Fineline Cube Mar 10, 2023

Olipharma, a small nucleic acid drug Contract Development and Manufacturing Organization (CDMO) based in Suzhou,...

Company Drug

Inventiva and Chia Tai Tianqing File Clinical Trial for Lanifibranor with CDE

Fineline Cube Mar 10, 2023

France-based Inventiva S.A. and China’s Chia Tai Tianqing have filed a clinical trial application with...

Company Drug

Simcere Pharmaceutical Initiates Clinical Study for Bispecific Antibody SIM0237 in Advanced Tumors

Fineline Cube Mar 10, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the first patient in (FPI) a clinical...

Company Deals

AusperBio and Asymchem Form Strategic Partnership for New Drug R&D and Services

Fineline Cube Mar 10, 2023

China-based firms AusperBio and Asymchem (SHE: 002821, HKG: 6821) have entered into a strategic partnership...

Policy / Regulatory

NHSA’s 2022 Healthcare Security Report Reveals Break-Even Performance

Fineline Cube Mar 10, 2023

The National Healthcare Security Administration (NHSA) has released its annual “Healthcare Security Development Statistical Bulletin”...

Company Drug

Bio-Thera Solutions Initiates Phase I Study for Trop2-Targeting ADC BAT8008

Fineline Cube Mar 10, 2023

China-based Bio-Thera Solutions, Ltd (SHA: 688177) has announced the first patient dosing in a multi-center,...

Company Drug

Astellas and Seagen File for NMPA Approval of Enfortumab Vedotin for Urothelial Carcinoma

Fineline Cube Mar 10, 2023

Japan-based Astellas Pharma Inc. (TYO: 4503) and US biotech Seagen Inc. (Nasdaq: SGEN) have announced...

Posts pagination

1 … 579 580 581 … 693

Recent updates

  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
  • Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
  • Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.